KPH Healthcare Services, Inc. v. Gilead Sciences, Inc. et al

  1. October 31, 2022

    Direct HIV Med Buyers Seek OK Of $10.8M Bristol-Myers Deal

    A putative class of direct HIV medication buyers asked a California federal judge to give final approval to a $10.8 million deal that would end claims that Bristol-Myers Squibb engaged in anti-competitive conduct to block generics competition and keep the medication's prices artificially high.

  2. June 06, 2022

    Bristol-Myers Inks $10.8M Deal In Direct Buyers' Antitrust Suit

    A California federal judge gave his blessing Friday to a $10.8 million settlement resolving direct buyers' claims alleging Bristol-Myers Squibb engaged in anti-competitive conduct to block generics competition and keep HIV medication prices artificially high.

  3. February 11, 2021

    Gilead, Bristol-Myers Say Direct Buyers Antitrust Suit Too Late

    Gilead Sciences and Bristol-Myers Squibb urged a California federal judge Thursday to nix direct buyers' claims alleging the pharmaceutical companies engaged in anti-competitive conduct to block generic competition and keep HIV medication prices artificially high, arguing the suits should be sent to arbitration or thrown out as time-barred.

  4. October 07, 2020

    Gilead Accused Of Antitrust Scheme Over HIV Meds

    Gilead Sciences Inc. schemed to monopolize the market for drugs commonly used to treat HIV and forced direct buyers to overpay for the medications as a result, a new proposed class action lawsuit alleges.